Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance

  • Maria Secrier
  • , Xiaodun Li
  • , Nadeera De Silva
  • , Matthew D. Eldridge
  • , Gianmarco Contino
  • , Jan Bornschein
  • , Shona Macrae
  • , Nicola Grehan
  • , Maria O'Donovan
  • , Ahmad Miremadi
  • , Tsun Po Yang
  • , Lawrence Bower
  • , Hamza Chettouh
  • , Jason Crawte
  • , Núria Galeano-Dalmau
  • , Anna Grabowska
  • , John Saunders
  • , Tim Underwood
  • , Nicola Waddell
  • , Andrew P. Barbour
  • Barbara Nutzinger, Achilleas Achilleos, Paul A.W. Edwards, Andy G. Lynch, Simon Tavaré, Rebecca C. Fitzgerald*, Ayesha Noorani, Rachael Fels Elliott, Jamie Weaver, Caryn Ross-Innes, Laura Smith, Zarah Abdullahi, Rachel De La Rue, Alison Cluroe, Shalini Malhotra, Richard Hardwick, Hugo Ford, Mike L. Smith, Jim Davies, Richard Turkington, Stephen J. Hayes, Yeng Ang, Shaun R. Preston, Sarah Oakes, Izhar Bagwan, Vicki Save, Richard J.E. Skipworth, Ted R. Hupp, J. Robert O'Neill, Olga Tucker, Philippe Taniere, Fergus Noble, Jack Owsley, Laurence Lovat, Rehan Haidry, Victor Eneh, Charles Crichton, Hugh Barr, Neil Shepherd, Oliver Old, Jesper Lagergren, James Gossage, Andrew Davies, Fuju Chang, Janine Zylstra, Grant Sanders, Richard Berrisford, Catherine Harden, David Bunting, Mike Lewis, Ed Cheong, Bhaskar Kumar, Simon L. Parsons, Irshad Soomro, Philip Kaye, Pamela Collier, Laszlo Igali, Ian Welch, Michael Scott, Shamila Sothi, Sari Suortamo, Suzy Lishman, Duncan Beardsmore, Hayley E. Francies, Mathew J. Garnett, John V. Pearson, Katia Nones, Ann Marie Patch, Sean M. Grimmond
*Šī darba korespondējošais autors
  • Cancer Research UK Cambridge Institute
  • University of Cambridge
  • Cambridge University Hospitals NHS Foundation Trust
  • University of Nottingham
  • Nottingham University Hospitals NHS Trust
  • University of Southampton
  • University Hospital Southampton NHS Foundation Trust
  • Queensland Institute of Medical Research
  • University of Queensland
  • Queen's University Belfast
  • University of Oxford
  • Northern Care Alliance NHS Group
  • University of Manchester
  • Wrightington, Wigan and Leigh NHS Trust
  • Royal Surrey County Hospital NHS Foundation Trust
  • Edinburgh Royal Infirmary
  • University of Edinburgh
  • University Hospitals Birmingham NHS Foundation Trust
  • University of Birmingham
  • University College London
  • Gloucestershire Hospitals NHS Foundation Trust
  • St. Thomas’s Hospital
  • King's College London
  • Karolinska Institutet
  • University Hospitals Plymouth NHS Trust
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
  • Norfolk and Waveney Cellular Pathology Network
  • Manchester University NHS Foundation Trust
  • University Hospitals Coventry and Warwickshire NHS Trust
  • North West Anglia NHS Foundation Trust
  • University Hospitals of North Midlands NHS Trust
  • Wellcome Trust
  • University of Melbourne

Zinātniskās darbības rezultāts: Devums žurnālam › Zinātniskais raksts (žurnālā) › koleģiāli recenzēts

333 Atsauces (Scopus)

Kopsavilkums

Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterogeneous cancer dominated by copy number alterations with frequent large-scale rearrangements. Co-amplification of receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; thus tailored combination RTK inhibitor (RTKi) therapy might be required, as we demonstrate in vitro. However, mutational signatures showed three distinct molecular subtypes with potential therapeutic relevance, which we verified in an independent cohort (n = 87): (i) enrichment for BRCA signature with prevalent defects in the homologous recombination pathway; (ii) dominant T>G mutational pattern associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern with evidence of an aging imprint. These subtypes could be ascertained using a clinically applicable sequencing strategy (low coverage) as a basis for therapy selection.

OriģinālvalodaAngļu
Lapas (no-līdz)1131-1141
Lapu skaits11
ŽurnālsNature Genetics
Sējums48
Izdevuma numurs10
DOIs
Publikācijas statussPublicēts - 1 okt. 2016
Ārēji publicētsJā

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

  1. 3. IAM — Laba Veselība un Labbūtība
    3. IAM — Laba Veselība un Labbūtība

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance”. Kopā tie veido unikālu nospiedumu.

Citēt šo